Research Analysts Issue Forecasts for PLX Q1 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Protalix BioTherapeutics in a research report issued on Monday, February 3rd. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of $0.03 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.02 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.05 EPS and Q4 2025 earnings at $0.06 EPS.

Separately, StockNews.com lowered Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday.

Protalix BioTherapeutics Stock Up 4.1 %

Shares of Protalix BioTherapeutics stock opened at $2.52 on Tuesday. The business has a fifty day simple moving average of $2.01 and a 200 day simple moving average of $1.43. The stock has a market cap of $185.56 million, a PE ratio of -19.38 and a beta of 0.75. Protalix BioTherapeutics has a 12 month low of $0.82 and a 12 month high of $2.54.

Institutional Investors Weigh In On Protalix BioTherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC boosted its holdings in shares of Protalix BioTherapeutics by 673.3% in the 2nd quarter. Squarepoint Ops LLC now owns 137,764 shares of the company’s stock valued at $161,000 after buying an additional 119,949 shares during the last quarter. AQR Capital Management LLC bought a new stake in Protalix BioTherapeutics during the second quarter worth $67,000. Virtu Financial LLC acquired a new stake in Protalix BioTherapeutics in the third quarter valued at $44,000. Sanctuary Advisors LLC bought a new position in shares of Protalix BioTherapeutics in the 3rd quarter valued at about $38,000. Finally, XTX Topco Ltd acquired a new position in shares of Protalix BioTherapeutics during the 3rd quarter worth about $36,000. 16.53% of the stock is owned by institutional investors.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.